Manakin Bio
San Diego, United States· Est.
AI‑driven rapid pathogen detection platform for clinical and public‑health diagnostics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
AI‑driven rapid pathogen detection platform for clinical and public‑health diagnostics.
Infectious Diseases
Technology Platform
AI‑augmented next‑generation sequencing platform that rapidly identifies pathogen nucleic‑acid signatures from clinical samples using proprietary deep‑learning classification algorithms.
Opportunities
Rapid, AI‑driven diagnostics meet rising demand for point‑of‑care infectious‑disease testing and antimicrobial stewardship across hospitals and public‑health agencies.
Risk Factors
Regulatory approval timelines, competition from established molecular diagnostic firms, and the need to demonstrate clinical utility at scale.
Competitive Landscape
Competes with Illumina, Thermo Fisher, Cepheid, and BioFire; differentiates through AI‑based real‑time analysis and a modular platform that can be deployed in both centralized labs and portable settings.